ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION

MA45620AUndetermined Publication Date: 2019-05-08F HOFFMANN LA ROCHE & CO AG

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MA45620
Authority / Receiving Office: MA · MA
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2017-05-09
Filing Date: 2017-06-28
Publication Date: 2019-05-08

Application Information

Patent Timeline

09 May 2017

Priority

28 Jun 2017

Application

MA45620

08 May 2019

Publication

MA45620A

IPC: C12N15/113

CPC: C12N15/1137; A61K31/7088; A61P19/02; A61P27/02; A61P25/00; A61P25/16; A61P25/28; A61P9/10

Inventors: HAGEDORN Peter; HUDLEBUSCH Heidi

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to antisense oligonucleotides (oligomers) complementary to htra1, leading to modulation of htra1 expression. Modulation of htra expression is beneficial for a range of medical disorders, such as age-related macular degeneration.

Need to check novelty before this filing date? Find Prior Art